Schroder Investment Management Group Grows Stock Position in Repligen Corporation $RGEN

Schroder Investment Management Group increased its stake in Repligen Corporation (NASDAQ:RGEN) by 123.2% in the third quarter, Holdings Channel reports. The institutional investor owned 460,609 shares of the biotechnology company’s stock after acquiring an additional 254,212 shares during the period. Schroder Investment Management Group’s holdings in Repligen were worth $61,570,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Brown Capital Management LLC increased its position in Repligen by 16.3% during the second quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock valued at $125,036,000 after acquiring an additional 141,241 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Repligen by 4.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 799,510 shares of the biotechnology company’s stock worth $106,826,000 after acquiring an additional 31,505 shares during the last quarter. Stephens Investment Management Group LLC lifted its holdings in shares of Repligen by 14.4% in the 3rd quarter. Stephens Investment Management Group LLC now owns 598,356 shares of the biotechnology company’s stock worth $79,982,000 after acquiring an additional 75,509 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Repligen by 6.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 458,820 shares of the biotechnology company’s stock worth $61,331,000 after purchasing an additional 28,716 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Repligen by 3,219.3% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock worth $51,422,000 after purchasing an additional 400,970 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Barclays reduced their price objective on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings lowered Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. Finally, UBS Group dropped their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $174.58.

Repligen Price Performance

Repligen stock opened at $121.79 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. The stock has a market cap of $6.86 billion, a price-to-earnings ratio of 143.28, a price-to-earnings-growth ratio of 2.49 and a beta of 1.14. The firm has a 50-day moving average of $148.33 and a two-hundred day moving average of $147.14. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $175.77.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company’s revenue was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In other Repligen news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the sale, the director directly owned 91,821 shares of the company’s stock, valued at $14,783,181. The trade was a 0.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.20% of the stock is currently owned by company insiders.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.